» Articles » PMID: 30093687

Identification of Recurrent USP48 and BRAF Mutations in Cushing's Disease

Abstract

Cushing's disease results from corticotroph adenomas of the pituitary that hypersecrete adrenocorticotropin (ACTH), leading to excess glucocorticoid and hypercortisolism. Mutations of the deubiquitinase gene USP8 occur in 35-62% of corticotroph adenomas. However, the major driver mutations in USP8 wild-type tumors remain elusive. Here, we report recurrent mutations in the deubiquitinase gene USP48 (predominantly encoding p.M415I or p.M415V; 21/91 subjects) and BRAF (encoding p.V600E; 15/91 subjects) in corticotroph adenomas with wild-type USP8. Similar to USP8 mutants, both USP48 and BRAF mutants enhance the promoter activity and transcription of the gene encoding proopiomelanocortin (POMC), which is the precursor of ACTH, providing a potential mechanism for ACTH overproduction in corticotroph adenomas. Moreover, primary corticotroph tumor cells harboring BRAF V600E are sensitive to the BRAF inhibitor vemurafenib. Our study thus contributes to the understanding of the molecular mechanism of the pathogenesis of corticotroph adenoma and informs therapeutic targets for this disease.

Citing Articles

X-linked ubiquitin-specific peptidase 11 (USP11) increases susceptibility to Cushing's disease in women.

Zhang T, Liu Y, Liu F, Guo K, Tang R, Ye J Acta Neuropathol Commun. 2025; 13(1):22.

PMID: 39910602 PMC: 11796047. DOI: 10.1186/s40478-025-01938-9.


Cushing syndrome.

Nieman L, Castinetti F, Newell-Price J, Valassi E, Drouin J, Takahashi Y Nat Rev Dis Primers. 2025; 11(1):4.

PMID: 39848955 DOI: 10.1038/s41572-024-00588-w.


New Trends in Treating Cushing's Disease.

Violetis O, Alexandraki K touchREV Endocrinol. 2024; 20(2):10-15.

PMID: 39526050 PMC: 11548364. DOI: 10.17925/EE.2024.20.2.3.


A Case of Cushing's Disease and a RET Pathogenic Variant: Exploring Possible Rare Associations.

Vaz de Assuncao G, Capela A, Fonseca L, Falcao Reis C, Amaral C Cureus. 2024; 16(10):e71058.

PMID: 39512978 PMC: 11541242. DOI: 10.7759/cureus.71058.


Grading and staging for pituitary neuroendocrine tumors.

Villa C, Birtolo M, Perez-Rivas L, Righi A, Assie G, Baussart B Brain Pathol. 2024; 35(1):e13299.

PMID: 39182993 PMC: 11669418. DOI: 10.1111/bpa.13299.


References
1.
Boutillier A, Sassone-Corsi P, Loeffler J . The protooncogene c-fos is induced by corticotropin-releasing factor and stimulates proopiomelanocortin gene transcription in pituitary cells. Mol Endocrinol. 1991; 5(9):1301-10. DOI: 10.1210/mend-5-9-1301. View

2.
Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, Hausch F . A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015; 21(3):276-80. DOI: 10.1038/nm.3776. View

3.
Karalis K, Venihaki M, Zhao J, van Vlerken L, Chandras C . NF-kappaB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem. 2004; 279(12):10837-40. DOI: 10.1074/jbc.M313063200. View

4.
Philips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P . Antagonism between Nur77 and glucocorticoid receptor for control of transcription. Mol Cell Biol. 1997; 17(10):5952-9. PMC: 232443. DOI: 10.1128/MCB.17.10.5952. View

5.
Huang C, Shi Y, Zhao Y . USP8 mutation in Cushing's disease. Oncotarget. 2015; 6(21):18240-1. PMC: 4621883. DOI: 10.18632/oncotarget.4856. View